Stay updated on Durvalumab in Resectable Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.

Latest updates to the Durvalumab in Resectable Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. This indicates a shift towards a more streamlined presentation of study information.SummaryDifference54%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
- Check23 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check30 days agoChange DetectedThe web page has been updated to a new version (v2.16.10), and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about the HHS Vulnerability Disclosure.SummaryDifference0.8%
- Check44 days agoChange DetectedThe service alert has been updated to reflect a planned maintenance period beginning on July 25th, with most services being unavailable for over 24 hours starting at 9 PM EDT. The revision number has also changed from v2.16.5 to v2.16.6.SummaryDifference2%
Stay in the know with updates to Durvalumab in Resectable Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.